Although hyperuricemia is a risk factor for the progression of renal dysfunction in patients with type 2 diabetes under SGLT2 inhibitor treatment [37], SGLT2 inhibitors have a decreasing effect on serum uric acid [38–42] due to an increase in urinary urate excretion through the upregulation of uric acid transporters of the renal tubules [43,44]. The gene discussed is SLC5A2; the disease is hyperuricemia.